Tumor-associated antigens within DRibbles vaccine (DRibbles)

Tumor-associated antigens within DRibbles vaccine represent a heterogeneous collection of proteins and peptides sequestered within autophagosomes derived from cancer cells (Ye et al., 2011). These autophagosomes are specifically enriched for Defective Ribosomal Products (DRiPs) and short-lived proteins (SLiPs), which are typically degraded by the proteasome and are often underrepresented in standard vaccine preparations (Sanborn et al., 2017). By packaging these antigens into double-membrane vesicles, the DRibbles platform protects them from rapid intracellular degradation and facilitates their efficient uptake by professional antigen-presenting cells, such as dendritic cells (Su et al., 2015). Once internalized, these antigens are processed and cross-presented on both MHC class I and class II molecules, triggering a robust and broad-spectrum immune response involving both CD4+ and CD8+ T cells (UbiVac, 2024). This multi-antigen approach is designed to address the challenge of tumor heterogeneity and minimize the risk of immune escape by targeting dozens of different tumor-specific markers simultaneously (Twitty et al., 2011). Clinically, this target is primarily associated with the investigational vaccine DPV-001, which has been evaluated in patients with non-small cell lung cancer and other solid tumors to enhance anti-tumor immunity (Sanborn et al., 2017).

Other names

Defective Ribosomal Products-containing autophagosome-rich blebsDRiPs-containing autophagosomesAutophagosome-based vaccine antigensDPV-001 antigens

DRibbles function by delivering a concentrated collection of tumor-associated antigens, including defective ribosomal products (DRiPs) and short-lived proteins (SLiPs), to dendritic cells for cross-presentation (Ye et al., 2011).